Christopher J. O’Callaghan

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Pascal Hammel, Mohamed Hebbar et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +14

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

James Perry, Normand Laperrière, Christopher J. O’Callaghan et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

Daniel J. Sargent, Harry S. Wieand, Daniel G. Haller et al. · Journal of Clinical Oncology · 2005 · 712 citations · Full text

Medicine, Biostatistics, Oncology +17

Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer

Mark D. Pegram, G. Konecny, Christopher J. O’Callaghan et al. · JNCI Journal of the National Cancer Institute · 2004 · 509 citations

Medicine, Oncology, Pharmacology +16

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

Juanita Crook, Christopher J. O’Callaghan, Graeme Duncan et al. · New England Journal of Medicine · 2012 · 497 citations · Full text

Medicine, Oncology, Urology +13